The marijuana industry has jumped into the limelight in recent years, and 2019 in particular has been a strong year so far for cannabis stocks. As key companies in the sector have started to see better results from major events like the opening of the Canadian market to recreational cannabis pro
USG (NYSE:USG) posted its quarterly earnings results on Thursday. The construction company reported $0.26 EPS for the quarter, missing the consensus estimate of $0.48 by ($0.22), MarketWatch Earnings reports. USG had a net margin of 2.75% and a return on equity of 13.93%. The business had revenu
24/7 Wall St. has put together a preview of a few major companies scheduled to report their quarterly results this coming week. The broad markets closed out last week with the Dow and S&P 500 holding near all-time highs. On the other hand, the Nasdaq fell behind and gave back some of its gains. A strong earnings showing from these stocks could help the markets reach even higher highs.
When an industry enjoys significant growth, individual stock valuations often rise with the tide. This firm’s inability to grow profits amidst record industry revenues raises a red flag. Add in significant competition, lagging margins, and an overvalued stock price, and it’s hard to justify any bull case. Nevertheless, this stock is up 48% over the past year. For these reasons and more,....More>>>
The Federal Reserve raised its target of the federal-funds rate, the interest rate banks charge each other for overnight loans, by a quarter point to a range of 0.75% to 1%, and thats great news for Warren Buffetts Berkshire Hathaway (BRK.B) and its shareholders. As a bondholder, owner of insurance companies and an investor in big banks, Berkshire profits from rising interest rates in a number....More>>>
Unsatisfied with the status quo, the intrepid business leaders on Forbes’ second annual Global Game Changers list are transforming their industries and changing the lives of billions of people around the globe.
These trailblazers are re-imagining countless facets of our lives, from the way we think about our health (23andMe’s Anne Wojcicki) to the way we tackle....More>>>
Berkshire Hathaway CEO Warren Buffett (Trades, Portfolio) extolled many of his portfolio holdings for repurchasing their shares, “some quite aggressively,” in his 2016 annual letter. Buffett, who is price-conscious and won’t repurchase his own companies’ shares at more than 1.2 times book value, a statement he last made good on in 2012, approved of his investees’....More>>>
Esperion Therapeutics (NASDAQ:ESPR) key attraction is that the market that its lead candidate targets - LDL-C reduction - once had Lipitor, a drug that generated $13bn at peak for Pfizer (NYSE:PFE). The difference is that Lipitor and a number of similar drugs are stat
Qiagen (NYSE: QGEN) is one of 91 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its peers? We will compare Qiagen to related companies based on the strength of its valuation, profitability, risk, dividends, ana
The American Society for Clinical Oncology (ASCO) annual meeting doesn't start for a few weeks, but a few companies made big moves on Thursday based on data in their abstracts that were released Wednesday evening. Here's a breakdown of the pops and drops and a look at what to expect when ASCO ki
Ultragenyx (NASDAQ:RARE), which we recommended as a buy in October 2017 when it was trading at 52-week lows, has been up 50% since our recommendation. We recommended it on the basis of an upcoming approval of its Sly syndrome treatment MEPSEVII in November - which hap